The American Diabetes Association (ADA) “Standards of Care in Diabetes” is based on a complete review of the relevant literature and is intended to provide clinicians, researchers, policy makers, and other interested individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. The ADA Professional Practice Committee updates the Standards of Care annually and strives to include discussion of emerging clinical considerations. Access the 2025 Standards of Care at diabetesjournals.org/care/issue/48/Supplement_1.

The 2025 Clinical Update Conference will be held at the Omni Orlando Resort at ChampionsGate from 31 January to 2 February. This conference is designed for health care professionals who provide clinical care and education for people with diabetes. For more information, please visit professional.diabetes.org/clinical-update-conference.

The 85th annual ADA Scientific Sessions will be held in Chicago, IL, 20–23 June 2025, at the McCormick Place Convention Center. Registration and housing are now open. For more information, please visit professional.diabetes.org/scientific-sessions.

This special collection of articles published in the December issue of Diabetes Care focuses on the Treatment of Booking Gestational Diabetes Mellitus (TOBOGM) study, which examines the effects of early diagnosis and intervention for women with gestational diabetes mellitus (GDM) detected during their initial prenatal visits. These articles provide key insights into improving care for women with GDM. To access the collection, visit diabetesjournals.org/collection/2624/TOBOGM-Study.

With the advent of newer, more effective therapies, interest is growing in the clinical management of obesity. A new Diabetes Spectrum From Research to Practice section reviews the rapidly changing landscape of obesity medicine, with a focus on the expanding armamentarium of pharmacotherapies. Articles in this timely collection review first-generation medications that still play an important role, game-changing second-generation drugs from the glucagon-like peptide 1 receptor agonist class, and the use of obesity drugs in the pediatric population. To access the special collection, as well as the full issue, visit diabetesjournals.org/spectrum.

A recently published ADA statement discusses the use of compounded GLP-1 RA (glucagon-like peptide 1 receptor agonist) and dual GIP/GLP-1 RA (glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist) medication classes. The statement recommends against using compounded GLP-1 and dual GIP/GLP-1 RA products that are not approved by the U.S. Food and Drug Administration, due to uncertainty about their content, safety, quality, and effectiveness. The statement can be accessed at doi.org/10.2337/dci24-0091.

Join our host, Dr. Neil Skolnik, as he leads a comprehensive exploration into the world of low- and no-calorie sweeteners in this special podcast series. In the third episode, Dr. Skolnik explores the role of sugar as the root cause of obesity. This series offers valuable clinical insights supported by an independent educational grant from Heartland Food Group, the maker of the Splenda group of products. For more information, please visit diabetesjournals.org/journals/pages/nonnutritive-sweeteners.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.